Hirst III Professors of Oncology in Pathology and members of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, and published Nov. 20 in Nature Communications, found that the absence ...

Pathologists at Institut Curie are now using Ibex's AI tools when diagnosing prostate cancer to enhance accuracy ... It's a ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study. The results could potentially lead to new therapies ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by scientists at Weill Cornell Medicine.

Deep Bio, a leader in artificial intelligence for digital pathology, announced a collaboration to integrate its prostate ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, ...

BRCA mutations are inextricably linked with breasts, but they can also lead to cancer in the pancreas, the prostate, and ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by ...

Researchers have identified a new role for the enzyme EZH2 in promoting the progression of aggressive, treatment-resistant ...

Hirst III Professors of Oncology in Pathology and members of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. The scientists found that the absence of a protein called PKCλ/ι in ...

The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.